Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | BRD2 | P25440 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL508753 | 0.86 | SMN1; SMN2 (0.36) | SMN1; SMN2CYP2D6CYP2C9CHRM2CHRM4 | |
| SCHEMBL29348305 | 0.84 | — | — | |
| SCHEMBL718764 | 0.84 | PIK3CD (0.41) | PIK3CDSMN1; SMN2BRD4BRD2CYP2D6 | |
| SCHEMBL21278138 | 0.79 | PIK3CD (0.41) | PIK3CDSMN1; SMN2BRD4BRD2CYP2D6 | |
| SCHEMBL21500436 | 0.77 | PIK3CD (0.40) | PIK3CDSMN1; SMN2BRD4BRD2CYP2D6 | |
| SCHEMBL25470434 | 0.73 | — | — | |
| SCHEMBL1698550 | 0.73 | SMN1; SMN2 (0.41) | PIK3CDSMN1; SMN2BRD4BRD2CYP2D6 | |
| SCHEMBL29105088 | 0.71 | SMN1; SMN2 (0.31) | SMN1; SMN2CYP2D6CYP2C9 | |
| SCHEMBL21895773 | 0.71 | — | — | |
| SCHEMBL22268217 | 0.71 | SMN1; SMN2 (0.36) | PIK3CDSMN1; SMN2BRD4BRD2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190119288-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119288-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, SLC10A1, HDGF | PIK3CD 1573/4885SMN1; SMN2 4688/4885BRD4 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.